Regeneron’s Inmazeb gets FDA approval for Ebola treatment
Inmazeb, which was previously called REGN-EB3, is now the first treatment to have been approved by the FDA for Ebola. The antibody cocktail has been indicated for the
Inmazeb, which was previously called REGN-EB3, is now the first treatment to have been approved by the FDA for Ebola. The antibody cocktail has been indicated for the
Approved by the institution’s board of executive directors, the financing is expected to support the vaccination of up to a billion citizens in the countries, said the World
The cohort is evaluating the antibody-drug conjugate PADCEV (enfortumab vedotin-ejfv) for patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor
True North met both primary endpoints, demonstrating highly statistically significant and clinically meaningful results for clinical remission compared to placebo at induction at Week 10 (18.4% versus 6.0%;
AFFINE is a global Phase 3, open-label, multicenter, single arm study that will evaluate the efficacy and safety of giroctocogene fitelparvovec in patients with moderately severe to severe
With the IND approval in place, the company expects to launch a phase 2b/3 sequential clinical trial of AB201 in the fourth quarter of 2020. The phase 2b
As a result, the Company believes its timelines for both filing an Investigational New Drug (“IND”) application and the commencement of the Phase 1 study will proceed on
ET140203 follows on the experience gained from Eureka’s study of ET140202. ET140202 and ET140203 utilize Eureka’s proprietary ARTEMIS cell receptor platform engineered with a TCR-mimic antibody to target
This approval is based on a pre-specified interim analysis from the Phase 3 CheckMate -743 trial in which Opdivo + Yervoy (n=303) demonstrated superior overall survival (OS) versus
Farxiga is an oral, once-daily sodium-glucose co-transporter-2 inhibitor (SGLT2 inhibitor). Its breakthrough therapy designation in chronic kidney disease was driven by the findings of phase 3 DAPA-CKD trial.